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Abstract
Distinct mechanisms are used by viruses to interact with cellular miRNAs. The role of microRNAs
in viral replication and persistence ranges from viral-encoded microRNAs to suppressors of RNA
interference. Viruses can also exploit cellular miRNAs for influencing cellular metabolism to ensure
efficient replication or latency. In particular, two recent studies provide examples of how HTLV-1
may co-opt or subvert cellular miRNAs for persistent replication and oncogenic purposes. The
pathways modulated by these described miRNAs are critically involved in apoptosis, proliferation
and innate immune response.
Biogenesis of miRNAs
MicroRNAs are initially transcribed by RNA polymerase II
as a primary miRNA (pri-miRNA) transcript and proc-
essed in the nucleus by RNase III enzyme Drosha and its
cofactor DGCR8 [1-4]. Cleavage of the pri-miRNA by the
Drosha-DGCR8 heterodimer generates a 60–70 nucle-
otide precursor miRNA (pre-miRNA), which is then trans-
ported to the cytoplasm by the nuclear export factor
exportin 5 and GTP-bound Ran. Cytoplasmic pre-miRNA
is further recognized by RNase III enzyme Dicer bound to
its cofactor TRBP, and the pre-miRNA is cleaved into a
mature miRNA. Finally, loading of the miRNA into the
RNA-induced silencing complex (RISC) allows the miR-
RISC to target cognate mRNA via imperfect base comple-
mentarity. miR-RISC can induce the cleavage of or may
inhibit the translation of targeted mRNAs.
There is some promiscuity amongst the several hundreds
of cellular miRNAs, each miRNA can potentially target
many discrete mRNAs, thereby modulating a broad spec-
trum of biological functions. Indeed, RNA interference is
a major mechanism used to control viral infections in
plants and invertebrates [4]. As a counter play to the cell's
RNAi, viruses encode suppressors of RNA silencing, which
target several key steps in the RNAi process [5,6]. Compel-
ling evidence that this process also applies to mammalian
cells and viruses is presently accumulating in the
literature [7].
Biological roles of virus-encoded non-coding 
RNAs
The first evidence of virus-encoded miRNAs emerged from
studies of Herpesviruses (e.g. Epstein-Barr virus encoded
microRNAs [8,9]). These viral miRNAs exert a wide variety
of functions ranging from stimulation of proliferation,
inhibition of apoptosis, maintenance of latency, regula-
tion of immune response and cellular metabolism. For
example, miR-I encoded by the herpes simplex virus 2
(HSV 2) has a critical role in neurovirulence through
modulation of ICP34.5 expression [10]. On the other
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hand, miR-K12-10 encoded by Kaposi sarcoma-associated
herpesvirus (KSHV) plays a key role in cellular transfor-
mation through downregulation of Kaposin mRNA trans-
lation [9,11]. Non-herpesviruses such as Simian Virus 40
(SV40) can also encode a miRNA which reduces the sus-
ceptibility of infected cells to lysis by cytotoxic T cells,
allowing the virus to evade the host immune response
[12]. Additionally, adenovirus VA1 noncoding RNA is not
a virus-encoded miRNA, but is able to subvert the cell's
RNAi pathway by competing with cellular pre-miRNAs for
exportin-5 in the nucleus as well as by binding Dicer in
the cytoplasm [13]. VA1 RNA also interacts with PKR
(interferon-inducible double-stranded RNA-dependent
protein kinase), thereby blocking its activation and the
subsequent phosphorylation of eukaryotic translation-
initiation factor 2α (eIF2α).
Viruses can be targeted by cellular miRNAs
Given the prevalence of miRNA genes and the short six-
nucleotide seed pairing that is needed to establish
miRNA-mRNA interactions, viral genomes are also likely
targets of human cellular miRNAs [14]. Initial evidence
supporting this idea was illustrated by the binding of the
host-cell's miRNA miR-32 to a site in primate foamy virus
type 1 (PFV-1) RNA, which restricted viral RNA accumula-
tion [15]. The PFV-1 Tas protein counteracted this mecha-
nism and functioned as a silencing suppressor to relieve
this repression and allowed PFV-1 replication.
Surprisingly, the interaction of viral genomes with cellular
miRNAs may also promote rather than inhibit viral repli-
cation. Thus, the binding of liver-specific miR-122 to the
5' end of hepatitis C virus (HCV) RNA increased viral RNA
levels, probably owing to a stimulation of viral replication
or to the re-localization of viral RNA [16,17]. Interferon-
beta (IFNβ) treatment reduced miR-122 but increased the
expression of miR-1/miR-30/miR-128/miR-196/miR-
296/miR-351/miR-431/miR-448 miRNAs [18]. Similarly,
the introduction of synthetic miRNA mimics correspond-
ing to these 8 miRNAs into cells reproduced the antiviral
effects of IFNβ on HCV replication. Conversely, neutrali-
zation of these miRNAs reduced the antiviral effects of
IFNβ against HCV. Moreover, inoculation of miR-122
antisense oligonucleotides into mice resulted in the inhi-
bition of cholesterol biosynthesis and HCV replication
[19,20].
The ability of mammals to regulate retroviruses like HIV-
1 has been intensely debated [3,21]. Recent evidence that
HIV-1 replication can be promoted by lowered expression
of Dicer and Drosha supports a role of the miRNA silenc-
ing machinery in controlling viral infection [22]. In fact,
the 3' ends of HIV-1 mRNAs are targeted by a cluster of
cellular miRNAs (miR-28, miR-125b, miR-150, miR-223
and miR-382), which inhibit HIV-1 protein translation
and viral production [23]. Since these miRNAs are upreg-
ulated in resting CD4+ T cells, the RNAi machinery may
also contribute to viral latency. Given that specific inhibi-
tors of these miRNAs substantially counteract their effects
on the target mRNAs, RNA interference may potentially be
useful for purging the HIV-1 reservoir of latent virus [24].
Targeting of cellular miRNAs by HTLV-1
Viruses can also exploit cellular miRNAs for influencing
cellular metabolism, proliferation, apoptosis and, ulti-
mately, transformation [2]. For example, the Epstein Barr
virus (EBV) infection of human B lymphocytes increases
miR-155 [25] and miR-146a [26] expression through a
mechanism that, at least in part, involves latency mem-
brane protein 1 (LMP1). Similarly, increased expression
of the BIC/miR155 and other oncogenic miRNA tran-
scripts in animal lymphomas due to retroviral integra-
tions have also been documented [27-29]. However,
despite the few examples of subversion of cellular miRNA
by viruses, the field of viral oncogenesis mediated through
miRNA-expression remains insufficiently explored. The
papers by Pichler et al. [30] and by Yeung et al. [31] rep-
resent the first reports linking Human T-lymphotropic
virus type 1 (HTLV-1) infection with the modulation of
human miRNA expression.
HTLV-1 infects about 10–20 million people worldwide
and, in a significant proportion of them (~2–4%), causes
either adult T cell leukemia (ATL) or HAM/TSP (HTLV-
associated myelopathy/Tropical Spastic Paraparesis).
HTLV-1 infects and replicates in CD4+ and CD8+ T lym-
phocytes [32] as well as in dendritic cells [33]. HTLV-1
persistence and replication critically involves the virus-
encoded Tax protein [34,35]. Amongst a broad variety of
functions, Tax activates transcription of viral and cellular
genes (e.g. TNF-α), accelerates cell cycle progression,
interferes with apoptosis, inhibits checkpoints and
induces DNA damage. To carry out these functions, Tax
interacts with and modulates the activity of more than
100 cellular proteins (recently reviewed by Boxus et al
[36]). The new findings from Pichler et al. and Yeung et al.
add another level of complexity by identifying miRNAs as
being either directly activated by Tax or associated with
HTLV-1 induced cell transformation.
The approaches used to narrow down the spectrum of
candidate miRNAs in the two studies were different. Pich-
ler et al. selected a limited number of miRNAs having
links with cancer and being overexpressed in regulatory T
lymphocytes. Their rationale for miRNA selection was
that the phenotype of Tregs resembles that of ATL cells.
RT-PCR quantification identified upregulated (miR-21,
miR-24, miR-146a, miR-155) and repressed (miR-223)
miRNAs in a series of cell lines derived from ATL patients,
HAM/TSP patients and HTLV-1 or Tax transformed cells.Retrovirology 2008, 5:101 http://www.retrovirology.com/content/5/1/101
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Expression of one of these, miR-146a, was directly acti-
vated by Tax through the proximal NF-κB site of the
MIRN146A gene promoter.
Yeung et al. profiled 327 human miRNAs in 7 HTLV-1
transformed cell lines and 4 PBMC samples from acute
ATL patients. Among 15 miRNAs whose expression was
consistently modified compared to paired controls, only 3
(miR-93, miR-130b and miR-18a) were also induced
upon the activation of normal PBMCs with phorbol myr-
istate acetate. The authors then confirmed the differential
expression of miR-93 and miR-130b using qRT-PCR.
Computational analysis and luciferase reporter assays
demonstrated that the p53-inducible tumor suppressor
protein (TP53INP1) was a target shared by both miR-93
and miR-130b. Consistently, antagomirs for miR-93 and
miR-130b (used to knock down the level of miR-93 and
miR-130b in cells) restored TP53INP1 expression and
increased the apoptosis of HTLV-1 transformed MT4 cells.
Conversely, siRNA knock-down of TP53INP1 rescued
MT4 from cell death induced by the miR-93 and miR-
130b antagomirs. Increased expression of miR-130b
occurs at least partly through transcriptional activation by
Tax. Finally, Yeung et al. also reported a series of miRNAs
that are repressed in ATL cells.
HTLV-1 upregulates miRNAs involved in 
proliferation, apoptosis and immune response
Although technical procedures and methodological
approaches were different, several identical miRNA
changes were identified in both studies. Given the com-
plexity of the biological processes and the reported data-
sets, we focus in figure 1 on a selected number of relevant
miRNAs reported in the two studies that are overexpressed
in ATL (miR-93, miR-130b, miR-155 and miR-146a).
These miRNAs target genes (TP53INP1, SMAD5, IRAK6/
TRAF1) are involved in apoptosis, cell proliferation or
transformation, and the regulation of immune response.
A first salient outcome from the Pichler and Yeung reports
is that HTLV-1 directly modulates the expression of at
least two miRNAs by transactivating the miR-130b and
miR-146a promoters. These data show examples of how
viruses may directly modulate the transcription of cellular
miRNAs, possibly to favor replication and/or oncogenic-
ity. Considering that the HTLV-1 Tax protein is known to
activate a very long list of genes through NFκB/CREB/SRF
[35], it is expected that additional miRNAs could be
directly modulated by Tax, through the transactivation of
their cognate promoters. We can also speculate whether
other steps in the biogenesis of miRNA may be under the
control of HTLV-1 encoded proteins, such as Rex for
nuclear export or NC for encapsidation. Further investiga-
tions are definitely required to test these predictions.
A second striking observation is that a single transcript (i.e.
TP53INP1) is targeted by 3 different miRNAs (miR93,
miR130b and miR155) that are overexpressed in ATL cells.
TP53INP1, whose transcription is activated by p53, induces
cell cycle arrest in G1 and enhances p53-mediated apopto-
sis [37]. The role of TP53INP1 in oncogenesis has been
reported in a series of models. In pancreatic cancer,
TP53INP1 is repressed by miR-155, and its restoration
inhibits tumor development [1]. Growth of colorectal
tumors is exacerbated in TP53INP1-deficient mice [38].
TP53INP1's expression is reduced during the development
of breast cancer [39], gastric cancer [40], pancreatic cancer
[1] and melanoma [41], but curiously increased in thyroid
cancer [42]. The convergence of multiple miRNAs onto a
single target reinforces the idea that TP53INP1 could also
be a relevant factor for HTLV-1 leukemogenesis.
Besides its effects on TP53INP1, miR155 also targets genes
critically involved in cellular proliferation and transfor-
mation. In fact, higher expression of miR-155 has been
exemplified in several types of hematopoietic malignan-
cies including B-cell and Hodgkin's lymphoma [4,43,44].
Overexpression of miR-155 causes myeloproliferative dis-
orders or B cell lymphoma in mouse models. Mice lacking
miR-155 exhibit defective humoral responses after immu-
nization, consistent with a specialized function for miR-
155 during infection [45,46]. In T lymphocytes, miR-155
regulates T cell lineage fate by promoting T helper type 1
Overview of 4 miRNAs overexpressed in ATL cells and their  targeted mRNAs: TP53INP1, Smad5 and IRAK6/TRAF1 Figure 1
Overview of 4 miRNAs overexpressed in ATL cells 
and their targeted mRNAs: TP53INP1, Smad5 and 
IRAK6/TRAF1. These genes are critically involved in path-
ways important for viral persistence and oncogenicity. Tax 
directly transactivates the miR-146a (through a NF-κB site) 
and miR-130b promoters. Only one of these pathways 
Tax→miR130b→TP53INP1→apoptosis has presently been 
demonstrated functionally.
Tax
miR93 miR130b miR155 miR146a
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(Th1) versus T helper type 2 (Th2) differentiation. BIC/
miR-155 is overexpressed in Treg cells, consecutive to
Foxp3-induced promoter activation. Consistent with its
association with an activated T cell phenotype, miR-155 is
absent from the HIV-1 latent reservoir [23]. miR-155 is
also involved in lymphocyte activation and the latency of
Epstein-Barr virus (EBV)-infected cells [47]. miR-155
expression in EBV-infected cells is dependent on NF-κB
signaling and requires a conserved AP-1 element in the
miR-155 promoter. Using luciferase reporter systems,
Smad5 was confirmed as a gene under the control of miR-
155 [47]. Smad5 is one of the 5 receptor-regulated Smads
which orchestrate transforming growth factor β (TGFβ)
signaling. TGFβ induces miR-155 expression and pro-
moter activity through Smad4 [48]. Conversely, the
knockdown of miR-155 suppresses TGFβ-induced cell
migration and invasion [49]. The involvement of miR-
155 in ATL further complicates the interplay between
HTLV-1 and the TGFβ pathway [50-52] but underscores
its critical role in transformation.
Another key player overexpressed in HTLV-1-infected ATL
cells is miR-146a. This miRNA was first identified as an
immune system regulator induced by lipopolysaccharide
(LPS) and proinflammatory cytokines (such as inter-
leukin 1 and tumor necrosis factor) [53,54]. miR-146 is
among the most highly expressed miRNAs in regulatory T
cells. Compared to Th2 and naïve T cells, miR-146 levels
are higher in Th1 cells. Amongst the growing list of con-
firmed target genes of mir-146, IRAK1 and TRAF6 adaptor
molecules are essential for Toll-like receptor and inter-
leukin 1 receptor signaling [55,56]. Reduction of IRAK1
and TRAF6 expression might therefore be involved in the
regulation of the innate immune response.
Conclusion
HTLV-1 has not yet been shown to encode a viral miRNA,
although potential candidate genes such as Hbz [57,58]
have not been sufficiently evaluated. In this context, it is
intriguing that the Hbz RNA, but not its encoded proteins,
promotes T cell proliferation [59]. Could this activity be
through an RNA-mediated mechanism similar to RNA
interference? The papers by Pichler et al [30] and Yeung et
al. [31] demonstrate how HTLV-1 modulates a series of
miRNAs, although only a few of them are commented on
here. What has not been mentioned here but should be
stressed is that a number of miRNAs are repressed in ATL
cells such as let-7 (a tumor repressor of Ras and Myc trans-
formation) or miR34b (inducing cell cycle arrest), further
amplifying the complexity of HTLV-1's interaction with
miRNAs in the transformation pathways. In another per-
spective, it could also be considered that HTLV-1 persists
in a limited population of cells characterized by a given
miRNA profile. This view of opportunistic viral persist-
ence has recently been illustrated for how HIV-1 latently
infects resting CD4 T-cells [23]. Further investigations of
confirmed and speculative interplays between HTLV-1
and small non-coding RNAs (figure 2) are merited.
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